- Trials with a EudraCT protocol (69)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
69 result(s) found for: Cyclic Peptide.
Displaying page 1 of 4.
| EudraCT Number: 2015-004207-22 | Sponsor Protocol Number: CLCZ696B2319 | Start Date*: 2017-04-06 | |||||||||||
| Sponsor Name:Novartis Pharma Services AG | |||||||||||||
| Full Title: Multicenter, open-label, study to evaluate safety, tolerability, pharmacokinetics and, pharmacodynamics of LCZ696 followed by a 52-week randomized, double-blind, parallel group, active-controlled s... | |||||||||||||
| Medical condition: Pediatric heart failure 1 month to <18 years old | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) FI (Completed) NL (Ongoing) SE (Completed) NO (Completed) ES (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) IT (Completed) FR (Completed) BG (Completed) PL (Completed) HU (Completed) HR (Completed) AT (Completed) PT (Completed) RO (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-003921-13 | Sponsor Protocol Number: 12/0368 | Start Date*: 2013-06-07 | |||||||||||
| Sponsor Name:University College London | |||||||||||||
| Full Title: COMbination therapy for PulmonAry hypertension using RacEcadotril (COMPARE). | |||||||||||||
| Medical condition: Pulmonary hypertension | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2006-004673-98 | Sponsor Protocol Number: ML 20538 | Start Date*: 2006-10-16 |
| Sponsor Name:Roche (Hungary) Ltd. | ||
| Full Title: Efficacy of Rituximab treatment in patients with rheumatoid arthritis having inadequate response to TNF blocker | ||
| Medical condition: To investigate the efficacy of treatment with Rituximab (MabThera®) in patients with active RA whose current treatment with one or more TNF-blocker (Etanercept - Enbrel®, Infliximab – Remicade® or ... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: HU (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2019-002351-42 | Sponsor Protocol Number: VIB4920.P0.S1 | Start Date*: 2020-01-13 | |||||||||||
| Sponsor Name:Viela Bio, Inc. | |||||||||||||
| Full Title: An Observational, Follow-on Study to the MEDI4920 (D5100C00002) Study to Evaluate the Duration of Clinical and Pharmacodynamic Efficacy of 12 weeks of Treatment with VIB4920 in Subjects with Modera... | |||||||||||||
| Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: PL (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-003333-95 | Sponsor Protocol Number: M14-465 | Start Date*: 2015-12-18 | |||||||||||
| Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
| Full Title: A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Backg... | |||||||||||||
| Medical condition: Moderately to Severely Active Rheumatoid Arthritis (RA) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SK (Trial now transitioned) ES (Ongoing) BG (Trial now transitioned) HU (Trial now transitioned) BE (Trial now transitioned) DK (Prematurely Ended) IE (Completed) PT (Trial now transitioned) GB (GB - no longer in EU/EEA) LV (Trial now transitioned) AT (Prematurely Ended) DE (Ongoing) PL (Trial now transitioned) FI (Completed) CZ (Trial now transitioned) HR (Trial now transitioned) LT (Trial now transitioned) GR (Trial now transitioned) FR (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-003334-27 | Sponsor Protocol Number: M13-545 | Start Date*: 2015-12-11 | |||||||||||
| Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
| Full Title: A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) Once Daily Monotherapy to Methotrexate (MTX) Monotherapy in MTX-Naïve Subjects with Moderately to Severely Active Rheumato... | |||||||||||||
| Medical condition: Moderately to Severely Active Rheumatoid Arthritis (RA) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SK (Completed) SI (Completed) ES (Ongoing) GR (Completed) LT (Completed) BE (Completed) CZ (Completed) IE (Completed) LV (Completed) PL (Completed) GB (GB - no longer in EU/EEA) PT (Completed) HU (Completed) FI (Prematurely Ended) RO (Ongoing) HR (Completed) BG (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2004-002620-18 | Sponsor Protocol Number: IM101-046 | Start Date*: 2005-05-13 |
| Sponsor Name:Bristol-Myers Squibb International Corporation | ||
| Full Title: A Multi-National Randomized, Double-Blind, Exploratory Study of Abatacept versus Placebo in Preventing the Development of Rheumatoid Arthritis in Adult Subjects with Undifferentiated Inflammatory A... | ||
| Medical condition: Rheumatoid Arthritis, NOS | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Completed) GB (Completed) BE (Completed) IT (Completed) ES (Completed) | ||
| Trial results: Removed from public view | ||
| EudraCT Number: 2015-004502-42 | Sponsor Protocol Number: UoL001145 | Start Date*: 2016-03-03 | |||||||||||
| Sponsor Name:University of Liverpool | |||||||||||||
| Full Title: SATURN: An exploration of the dynamic interaction between IL-17, IL-17 inhibition with (secukinumab) and neutrophils in psoriatic arthritis in vitro and ex vivo with exploratory study on the potent... | |||||||||||||
| Medical condition: Psoriatic Arthritis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2019-004468-23 | Sponsor Protocol Number: version3.0 | Start Date*: 2020-02-10 |
| Sponsor Name:St George's, University of London | ||
| Full Title: Comparison of abatacept with tumor necrosis factor inhibitors in the treatment of rheumatoid arthritis pain: A phase IV trial | ||
| Medical condition: Rheumatoid arthritis | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (GB - no longer in EU/EEA) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2006-000854-32 | Sponsor Protocol Number: RA 2.0 | Start Date*: 2006-05-29 |
| Sponsor Name:Vienna Medical University | ||
| Full Title: Rituximab in Rheumatoid Arthritis in Patients Who Failed Therapy With TNF-Blockers | ||
| Medical condition: Rheumatoid Arthritis | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: AT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2010-019110-24 | Sponsor Protocol Number: CZOL446HDE43T | Start Date*: 2010-12-27 | |||||||||||
| Sponsor Name:Universitätsklinikum Erlangen | |||||||||||||
| Full Title: A PHASE 2, SINGLE-CENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF ZOLEDRONATE IN SUBJECTS WITH EROSIVE HAND OSTEOARTHRITIS | |||||||||||||
| Medical condition: Erosive hand osteoarthritis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2009-016987-34 | Sponsor Protocol Number: A3921069 | Start Date*: 2010-02-09 | |||||||||||
| Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | |||||||||||||
| Full Title: PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF CP-690,550 COMPARED TO METHOTREXATE IN METHOTREXATE-NAÏVE PATIENTS WITH RHEUMATOID ARTHRITIS | |||||||||||||
| Medical condition: Moderate to severe active Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Completed) BE (Completed) ES (Completed) DE (Completed) HU (Completed) CZ (Completed) PL (Completed) SK (Completed) BG (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-007023-26 | Sponsor Protocol Number: A3921044 | Start Date*: 2009-05-18 | |||||||||||
| Sponsor Name:Pfizer Inc. | |||||||||||||
| Full Title: PHASE 3 RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF CP 690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND METHOTREXATE | |||||||||||||
| Medical condition: CP 690,550 is being studied as a disease modifying antirheumatic drug for the treatment of moderate to severe active rheumatoid arthritis in adults. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) GR (Completed) BG (Completed) PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-000050-38 | Sponsor Protocol Number: CAIN457F2342 | Start Date*: 2015-07-07 | |||||||||||
| Sponsor Name:Novartis Pharma Services AG | |||||||||||||
| Full Title: A Phase III, randomized, double-blind, placebo controlled multi-center study of subcutaneous secukinumab (150 mg and 300 mg) in prefilled syringe to demonstrate efficacy (including inhibition of st... | |||||||||||||
| Medical condition: Psoriatic Arthritis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: LT (Completed) IE (Completed) HU (Completed) NL (Completed) ES (Completed) DE (Completed) IT (Completed) AT (Completed) LV (Completed) DK (Completed) CZ (Completed) FI (Completed) EE (Completed) GR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2009-010208-27 | Sponsor Protocol Number: CLCZ696B2214 | Start Date*: 2009-06-29 | |||||||||||
| Sponsor Name:Novartis Farmacéutica S.A | |||||||||||||
| Full Title: Estudio aleatorizado, doble ciego, multicéntrico, de grupos paralelos, controlado con tratamiento activo de doce semanas de seguimiento para evaluar la eficacia, seguridad y tolerabilidad de LCZ696... | |||||||||||||
| Medical condition: Insuficiencia Cardiaca crónica | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Completed) NL (Completed) IT (Completed) PL (Completed) DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-003849-10 | Sponsor Protocol Number: CAIN457F2336 | Start Date*: 2015-03-17 | |||||||||||
| Sponsor Name:Novartis Pharma Services AG | |||||||||||||
| Full Title: A phase III, randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab (150 mg) in pre-filled syringe, with or without loading regimen, to demonstrate efficacy, saf... | |||||||||||||
| Medical condition: Psoriatic Arthritis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Completed) CZ (Completed) BE (Completed) BG (Completed) DE (Completed) GB (Completed) PL (Completed) FR (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-002202-31 | Sponsor Protocol Number: POL7080-002 | Start Date*: 2013-09-11 |
| Sponsor Name:Polyphor Ltd. | ||
| Full Title: A phase II, open-label, multi-center study to assess the tolerance, safety, efficacy and pharmacokinetics/pharmacodynamics (PK/PD) of POL7080 in the treatment of patients with acute exacerbation of... | ||
| Medical condition: Acute exacerbation of non-cystic fibrosis bronchiectasis due to Pseudomonas aeruginosa infection. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) ES (Prematurely Ended) DE (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2011-005036-26 | Sponsor Protocol Number: FXT-05 | Start Date*: 2011-11-29 | ||||||||||||||||||||||||||
| Sponsor Name:Funxional Therapeutics Ltd | ||||||||||||||||||||||||||||
| Full Title: An Exploratory Phase IIa Study to Investigate the Biological Activity of Oral FX125L in Adult Patients with Chronic Inflammatory Disease | ||||||||||||||||||||||||||||
| Medical condition: Asthma Chronic obstructive pulmonary disease Rheumatoid arthritis Psoriasis | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2011-002067-20 | Sponsor Protocol Number: RA0077 | Start Date*: 2012-06-13 | |||||||||||
| Sponsor Name:UCB Pharma SA | |||||||||||||
| Full Title: A multicenter, single blind, randomized parallel group study to assess the short and long term efficacy of certolizumab pegol plus methotrexate compared with adalimumab plus methotrexate in subject... | |||||||||||||
| Medical condition: Moderate to severe rheumatoid arthritis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) GB (Completed) HU (Completed) PT (Completed) AT (Completed) IE (Completed) CZ (Completed) ES (Completed) BG (Completed) FR (Completed) IT (Completed) GR (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-004002-25 | Sponsor Protocol Number: CAIN457F2318 | Start Date*: 2014-01-21 | |||||||||||
| Sponsor Name:Novartis Pharma Services AG | |||||||||||||
| Full Title: A phase III, randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab in autoinjectors, to demonstrate efficacy at 24 weeks and to assess the long term safety, tol... | |||||||||||||
| Medical condition: Psoriatic Arthritis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) IT (Completed) ES (Completed) NL (Completed) CZ (Completed) BG (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.